<DOC>
	<DOCNO>NCT00708084</DOCNO>
	<brief_summary>The aim study evaluate safety monoclonal antibody cocktail CL184 combination rabies vaccine compare human rabies immune globulin ( HRIG ) combination rabies vaccine healthy child adolescent .</brief_summary>
	<brief_title>Randomized Phase II Trial Safety Neutralizing Activity CL184 Rabies Vaccine Versus Human Rabies Immune Globulin ( HRIG ) Rabies Vaccine Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subjects free obvious healthproblems stable condition Male female subject age ≥5 ≤18 year Subject living , study , work close study referral site Parent legal representative sign write informed consent ; addition subject ≥12 year : sign assent form Prior history rabies exposure immunization ( rabies vaccine and/or immune globulin ) Acute infection disease within last 2 week History and/or family history clinically significant immunodeficiency autoimmune disease Any history know suspected anaphylaxis hypersensitivity reaction Planned immunization live vaccine next 3 month Chronic administration immunosuppressant immunemodifying drug within 6 month first dose investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Rabies post-exposure prophylaxis</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>